Recently, some small-molecule MGAT2 inhibitors with significant structural diversity may be used to treat obesity and metabolic diseases further (Devasthale and Cheng, 2018). The gene discussed is MGAT2; the disease is obesity due to melanocortin 4 receptor deficiency.